| 前收市價 | 66.45 |
| 開市 | 66.45 |
| 買盤 | 55.80 |
| 賣出價 | 61.70 |
| 拍板 | 275.00 |
| 到期日 | 2025-01-17 |
| 今日波幅 | 66.45 - 66.45 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 61 |
ReutersEisai and Biogen launch Alzheimer's drug Leqembi in China
Leqembi, which works by removing a toxic protein called beta amyloid from the brain, is the first Alzheimer's treatment proven to alter the course of the fatal, brain-wasting disease. Eisai has also collaborated with a major Chinese medical insurance firm to plan partial coverage of the drug cost, the companies said without naming the insurer. China approved the treatment in January after a standard approval from the U.S. Food and Drug Administration last July.
Investor's Business DailyEli Lilly Has Sprinted 55% Higher This Year — Is It A Buy On The Weight-Loss Opportunity?
Is Eli Lilly stock a buy as it looks to enter the obstructive sleep apnea treatment market? Is LLY stock a buy right now?
ZacksFDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.
